drugset / Trial / NCT05075057
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Hubei Provincial Center for Disease Control and Prevention · collabWuhan Institute of Biological Products Co., Ltd · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
Timeline
- Start
- 2021-10-08
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |